Showing results (341-350 of 378) with videos related to
Sort By:
Pageof 38
BJC Reports|November 8, 2024
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genesSarah Benafif, Ann-Britt Jones, Susan Merson, et al.European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trialChristopher M Nutting, Clare L Griffin, Paul Sanghera, et al.European Journal of Cancer (Oxford, England : 1990)|October 5, 2018
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)Christopher M Nutting, James P Morden, Matthew Beasley, et al.Journal of the National Cancer Institute|June 26, 2008
Multiple loci with different cancer specificities within the 8q24 gene desertMaya Ghoussaini, Honglin Song, Thibaud Koessler, et al.The Journal of Clinical Investigation|June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancerJuliet Carmichael, Ines Figueiredo, Bora Gurel, et al.Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.Clinical and Translational Radiation Oncology|December 1, 2022
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancerDavid J Thomson, Clare Cruickshank, Helen Baines, et al.The Journal of Clinical Investigation|December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquin Mateo, George Seed, Claudia Bertan, et al.Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.Cancer Discovery|April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Joaquin Mateo, Wei Yuan, et al.Pageof 38